Top scientists from eight companies discuss what it takes to maintain a creative and productive laboratory environment
Just five years later, however - after spending $5 million - Calgene plant pathologist Robert Goodman made a tough call: He decided to abort the whole project.
"It wasn't an easy decision to make," says Goodman, who until this summer was Calgene's vice president for research and development. "It was a good commercial opportunity, but we were unable to bring the technology on line fast enough. There were other projects that were closer to market and more certain commercially."